Imagabalin
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | PD-0332334; PD-332,334 |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H19NO2 |
Molar mass | 173.256 g·mol−1 |
3D model (JSmol) | |
| |
|
Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3][4][5][6] The drug is no longer under development.
See also
References
- ^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (July 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMC 3197737. PMID 21664606.
- ^ Larry Ereshefsky (2008). "Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models" (PDF) (Press release). p. 11. Retrieved 2012-04-22.
- ^ Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder". Archived from the original on 2021-03-28. Retrieved 2020-09-08.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder". Archived from the original on 2021-03-30. Retrieved 2020-09-08.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder". Archived from the original on 2021-03-31. Retrieved 2020-09-08.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Pfizer (2012-11-09). "A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder". Archived from the original on 2021-04-01. Retrieved 2020-09-08.
{{cite journal}}
: Cite journal requires|journal=
(help)
Categories:
- CS1 errors: missing periodical
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Anxiolytics
- Beta-Amino acids
- Calcium channel blockers
- GABA analogues
- Drugs developed by Pfizer
- Experimental drugs
- Abandoned drugs
- All stub articles
- Psychoactive drug stubs